CINECA IRIS Institutional Research Information System

Sfoglia per Autore  

Opzioni
Mostrati risultati da 61 a 80 di 229
Titolo Data di pubblicazione Autore(i) File
In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in anOncogenic BRAF-Induced Mouse Model of Melanoma 2011 Karreth FA; Tay Y; Perna D; Ala U; Tan SM; Rust AG; Denicola G; Webster KA; Weiss D; Perez-Mancera PA; Krauthammer M; Halaban R; Provero P; Adams DJ; Tuveson DA; Pandolfi PP
SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. 2011 Finley LW; Carracedo A; Lee J; Souza A; Egia A; Zhang J; Teruya-Feldstein J; Moreira PI; Cardoso SM; Clish CB; Pandolfi PP; Haigis MC
Pro-senescence therapy for cancer treatment. 2011 Nardella C; Clohessy JG; Alimonti A; Pandolfi PP
Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis. 2011 Nardella C; Lunardi A; Fedele G; Clohessy JG; Alimonti A; Kozma SC; Thomas G; Loda M; Pandolfi PP
Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. 2011 Sasaki AT; Carracedo A; Locasale JW; Anastasiou D; Takeuchi K; Kahoud ER; Haviv S; Asara JM; Pandolfi PP; Cantley LC
A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? 2011 Salmena L; Poliseno L; Tay Y; Kats L; Pandolfi PP
The APL Paradigm and the "Co-Clinical Trial" Project 2011 Nardella C; Lunardi A; Patnaik A; Cantley LC; Pandolfi PP
Treatment with 5-azacytidine accelerates acute promyelocytic leukemia leukemogenesis in a transgenic mouse model. 2011 Scaglioni PP; Cai LF; Majid SM; Yung TM; Socci ND; Kogan SC; Kopelovich L; Pandolfi PP
Pml represses tumour progression through inhibition of mTOR. 2011 Bernardi R; Papa A; Egia A; Coltella N; Teruya-Feldstein J; Signoretti S; Pandolfi PP
The nuclear bodies inside out: PML conquers the cytoplasm. 2011 Carracedo A; Ito K; Pandolfi PP
Functional Connection between Rad51 and PML in Homology-Directed Repair 2011 Boichuk S; Hu L; Makielski K; Pandolfi PP; Gjoerup OV
PTEN level in tumor suppression: how much is too little? 2011 Carracedo A; Alimonti A; Pandolfi PP
The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites. 2011 Pinton P; Giorgi C; Pandolfi PP
Haplo-insufficiency: a driving force in cancer 2011 Berger AH; Pandolfi PP
Targeting of the tumor suppressor GRHL3 by a miR-21-dependent proto-oncogenic network results in PTEN loss and tumorigenesis. 2011 Darido C; Georgy SR; Wilanowski T; Dworkin S; Auden A; Zhao Q; Rank G; Srivastava S; Finlay MJ; Papenfuss AT; Pandolfi PP; Pearson RB; Jane SM.
TSPYL5 suppresses p53 levels and function by physical interaction with USP7 2011 Epping MT; Meijer LA; Krijgsman O; Bos JL; Pandolfi PP; Bernards R
Amplification of the angiogenic signal through the activation of the TSC/mTOR/HIF axis by the KSHV vGPCR in Kaposi's sarcoma. 2011 Jham BC; Ma T; Hu J; Chaisuparat R; Friedman ER; Pandolfi PP; Schneider A; Sodhi A; Montaner S
Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis. 2011 Mduff FK; Hook CE; Tooze RM; Huntly BJ; Pandolfi PP; Turner SD
Mitochondria associated membranes (MAMs) as critical hubs for apoptosis 2011 Giorgi C; Wieckowski MR; Pandolfi PP; Pinton P
A continuum model for tumour suppression 2011 Berger AH; Knudson AG; Pandolfi PP
Mostrati risultati da 61 a 80 di 229
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile